Recap: Allogene Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Allogene Therapeutics (NASDAQ:ALLO) reported Q4 earnings with an EPS of $-0.51, missing estimates by -13.0% against an expected $-0.45. Revenue decreased by $26 thousand from the previous year. Despite beating EPS estimates in Q3 2023, which led to an 18.0% share price increase, this quarter's performance fell short.
March 14, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Allogene Therapeutics reported a Q4 EPS of $-0.51, missing estimates by -13.0%, with a slight revenue decrease from last year.
The missed earnings estimate and the decrease in revenue compared to the previous year are likely to negatively impact investor sentiment and potentially the stock price in the short term. Historical data shows that past earnings performance, such as the beat in Q3 2023, had a positive effect on the stock price, suggesting that missed estimates can have the opposite effect.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100